Pharsight

Oseni is owned by Takeda Pharms Usa.

Oseni contains Alogliptin Benzoate; Pioglitazone Hydrochloride.

Oseni has a total of 4 drug patents out of which 0 drug patents have expired.

Oseni was authorised for market use on 25 January, 2013.

Oseni is available in tablet;oral dosage forms.

Oseni can be used as method of treating diabetes comprising administering alogliptin, method of treating diabetes comprising administering a compound such as alogliptin.

The generics of Oseni are possible to be released after 04 June, 2029.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8288539	TAKEDA PHARMS USA	Dipeptidyl peptidase inhibitors	Mar, 2025 (1 year, 9 months from now)
US7807689	TAKEDA PHARMS USA	Dipeptidyl peptidase inhibitors	Jun, 2028 (5 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8173663	TAKEDA PHARMS USA	Dipeptidyl peptidase inhibitors	Mar, 2025 (1 year, 9 months from now)
US8637079	TAKEDA PHARMS USA	Solid preparation comprising alogliptin and pioglitazone	Jun, 2029 (6 years from now)

Do you want to check out OSENI patents from before 2022?

Drugs and Companies using ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE ingredient

Market Authorisation Date: 25 January, 2013

Treatment: Method of treating diabetes comprising administering a compound such as alogliptin; Method of treating diabetes comprising administering alogliptin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 12.5MG BASE;EQ 15MG BASE	TABLET;ORAL	Discontinued
EQ 12.5MG BASE;EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 12.5MG BASE;EQ 45MG BASE	TABLET;ORAL	Discontinued
EQ 25MG BASE;EQ 15MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE;EQ 30MG BASE	TABLET;ORAL	Prescription
EQ 25MG BASE;EQ 45MG BASE	TABLET;ORAL	Prescription